T3D-990

T3D-990 is a preclinical-stage small molecule being developed by T3D Therapeutics for the treatment of Alzheimer's disease. It is part of the company's pipeline of metabolic-based therapies designed to address neurodegeneration by targeting brain glucose metabolism and insulin resistance. While specific target details for T3D-990 are less publicized than the lead candidate T3D-959 (a dual PPAR delta/gamma agonist), it is developed under the same therapeutic philosophy of treating Alzheimer's as a 'Type 3 Diabetes' or a metabolic disorder of the brain. The compound aims to provide a disease-modifying effect by restoring metabolic health in the central nervous system.